This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 Feb 2014

AstraZeneca PLC Fourth Quarter and Full Year Results 2013

Pascal Soriot, Chief Executive Officer, commenting on the results, said:

"As expected, our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands. In the near term these headwinds will remain challenging, however I am confident that we can return to growth faster than anticipated and expect our 2017 revenues will be broadly in line with 2013.


“I’m pleased with the momentum we have built in 2013 against our strategic priorities, in particular our objective of achieving scientific leadership. We continue to focus our organisation on the areas that will drive growth, redeploying our resources to fund the promising late-stage pipeline, which nearly doubled in size during the last 12 months. The acquisition of Bristol-Myers Squibb’s share of our diabetes alliance strengthens our position in this important area and I am delighted that the business integration is progressing with such pace. We extend a warm welcome to our new colleagues who will help us maximise the potential of our diabetes portfolio.”


Significant progress made towards achieving scientific leadership.

• Pipeline now includes 11 new molecular entities in Phase III or registration; almost double compared with the previous year.


Pipeline and portfolio bolstered through business development in core therapeutic areas.

• Integration of the Bristol-Myers Squibb share of the diabetes alliance occurring at pace; business combination transaction completed on 1 February 2014.


2013 financial performance in line with our expectations and reflecting continuing impact of loss of exclusivity on several brands.


19 candidates for potential new Phase III starts in 2014–15.


Previously announced restructuring programme expanded to deliver a total $1.1 billion of annual benefits.


The Company expects a low-to-mid single digit percentage decline in revenue at constant exchange rates (CER) for 2014. Core EPS expected to decline in the teens.


The Board declares a second interim dividend of $1.90 per share, bringing the dividend for the full year to $2.80. The Board remains committed to the Company’s progressive dividend policy.

Related News